Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

NCT: NCT06121232 · RECRUITING

NCT IDNCT06121232
StatusRECRUITING
Start Date2023-11-02
Completion2028-06-01
SponsorM.D. Anderson Cancer Center (OTHER)
First posted
Last updated

Brief Summary

To learn if a process called neuromodulation can help to improve pain due to CIP

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑